The #1 Source for Information on Lobular Breast Cancer
What is Lobular Breast Cancer?
Lobular breast cancer, also called invasive lobular carcinoma (ILC), is the 2nd most common type of breast cancer, accounting for about 15% of all breast cancer diagnoses with over 48,000 cases diagnosed each year. It’s time to advance research to better understand ILC and its differences, and refine treatment for patients.
Hear from LBCA Scientific Advisory Board and other ILC experts
Watch the most recent webinars and interviews with SAB members, researchers, patient advocates, and more.
The Latest News
Research News
New ILC Clinical Trial with LBCA Scientific Advisory Board Chair, Dr. Jason Mouabbi on Metastatic ILC
LBCA encourages ILC patients to participate in breast cancer clinical trials to help ensure that there is sufficient participation by those with ILC to enable
Education & Advocacy
New ILC Focused Initiative at University of Colorado Anschutz Cancer Center
Researchers at the University of Colorado Anschutz Cancer Center have launched the Lobular Breast Cancer Initiative (LBCI), a new interdisciplinary program dedicated to advancing research
My ILC Story
My ILC Story: Meet Famke and Hear Her Lobular Breast Cancer Story
My name is Famke. I’m originally from Germany and have been living in the U.S. since 2008. I am now in the Bay Area and
ILC Clinical Trials
Patients with invasive lobular carcinoma (ILC) can advance understanding of the disease by joining clinical trials. Few trials focus solely on ILC due to its lower incidence (10-15% of all breast cancers), but participation is crucial. Increased research could help improve detection, treatment, prevention of metastasis, and ultimately, develop a cure.